-2022財年上半年收入增加17.0%，達到1370萬美元-
西安2022年8月1日 /美通社/ -- 西安天美生物科技股份有限公司（納斯達克代碼：BON）（"天美生物"或"公司"），一家在天然、健康和個人護理行業(yè)提供關(guān)鍵活性成分及解決方案的領(lǐng)先供應(yīng)商，今天宣布其截至2022年3月31日的6個月的半年度財務(wù)業(yè)績。
2022財年上半年財務(wù)亮點
管理層討論
"盡管疫情和當前宏觀經(jīng)濟狀況帶來了前所未有的挑戰(zhàn)，但我們對2022年的強勢開局和許多新舉措的好勢頭感到高興。" 天美生物的董事長兼CEO胡永衛(wèi)表示，"我們團隊采取定價措施以及持續(xù)的成本控制和市場戰(zhàn)略調(diào)整來抵消長期的外部壓力。我為我們團隊所取得的成就感到無比自豪。2022財年上半年里，在產(chǎn)品結(jié)構(gòu)向高附加值、高利潤率的產(chǎn)品轉(zhuǎn)變的同時，通過提高銷售價格，有效地將不斷上漲的原材料成本轉(zhuǎn)移到下游。香料原料、膳食補充劑和生物活性食品原料的平均售價同比分別上漲了64.1%、11.2%和79.2%。我們的毛利率一直保持穩(wěn)定上升趨勢，連續(xù)增長了2.4個百分點。"
"我們對公司近期的里程碑事件充滿期待。在本財年，我們的第三個生產(chǎn)基地玉門工廠正按計劃完成建設(shè)，預(yù)計將于2022年第四季度投入生產(chǎn)。建成投產(chǎn)后，香料原料和生物活性食品原料的生產(chǎn)能力將提升200%，年化總收入增長潛力為150%。此外，隨著我們成功推出用于調(diào)節(jié)和改善人類整體微生物組和消化系統(tǒng)健康的新型蔬菜益生菌固體飲料，以及用于女性健康的含水蘇糖和蘋果提取物的個人護理產(chǎn)品，預(yù)計追求自然健康的消費者需求將不斷增長。通過我們新的玉門工廠和銅川工廠的擴建加上新產(chǎn)品計劃，將使我們能夠有效地滿足更多客戶需求，加快全球業(yè)務(wù)擴張，并為我們的投資者創(chuàng)造持久的長期價值。"
2022上半年產(chǎn)品（按類別）與上年相比增長總結(jié)：
收入增加（減少） |
毛利潤增加（減少） |
|
香料原料 |
24.9 % |
53.9 % |
膳食補充劑（固體飲料） |
(28.5 %) |
(36.4 %) |
生物活性食品原料 |
171.8 % |
191.1 % |
香料原料
膳食補充劑（固體飲料）
生物活性食品原料
管理費用從截至2021年3月31日的六個月的679,635美元增加到2022年同期的998,943美元，增加了319,308美元，或大約47.0%，主要是由于我們在2021年7月完成IPO成為上市公司后增加了335,265美元的專業(yè)服務(wù)費，例如董事和高管責任保險、投資者關(guān)系管理等。
研究和開發(fā)費用從截至2021年3月31日的六個月的106,998美元增長至164,675美元，增長了57,677美元，或約53.9%。這一增長主要是由于將研發(fā)活動外包給外部咨詢公司的費用增加了69,022美元。
政府補貼以補貼形式獲得并確認為其他營業(yè)收入，在截至2022年3月31日和2021年3月31日的六個月里，總額分別為542,256美元和446,910美元。
凈利潤從截至2021年3月31日的六個月的230萬美元增加到2022年同期的250萬美元。
用于經(jīng)營活動的凈現(xiàn)金在截至2022年3月31日的六個月期間為130,577美元，2021年同期經(jīng)營活動產(chǎn)生的凈現(xiàn)金為200萬美元。
稀釋后每股收益（"EPS"）為0.30美元，2021年同期為0.40美元。
我們鼓勵投資者查閱公司完整的財務(wù)報表和相關(guān)的披露資料，以了解更多信息。這些材料可在https://www.sec.gov/edgar/browse/?CIK=1816815&owner=exclude.中查閱。
報告期后事件
投資者電話會議和網(wǎng)絡(luò)直播
討論公司2022年上半年財務(wù)業(yè)績的網(wǎng)絡(luò)直播將于2022年8月1日美國東部時間上午9:00開始。網(wǎng)絡(luò)直播和相關(guān)PPT的獲取可以訪問公司的投資者網(wǎng)站 https://ir.bnlus.com/events-presentations/。網(wǎng)絡(luò)會議也可通過此鏈接進入：https://event.choruscall.com/mediaframe/webcast.html?webcastid=1sM1QUxQ 對于無法觀看網(wǎng)絡(luò)直播的人，在活動結(jié)束后公司將在網(wǎng)站上提供錄制版本。
預(yù)先登記：https://dpregister.com/sreg/10169993/f3e46b2118
預(yù)先登記的呼叫者將得到一個會議密碼和獨有PIN碼，可以立即進入電話會議并繞過接線員。與會者可以在任何時候進行預(yù)先登記，包括在電話會議開始后。
無法互聯(lián)網(wǎng)接入或無法預(yù)先登記的人可以通過以下電話撥入：
美國免費電話：1-866-777-2509
國際收費電話：1-412-317-5413
西安天美生物有限公司
西安天美生物專注于膳食營養(yǎng)補充劑的生物活性成分的生產(chǎn)，如為食品制造商提供天然益生元；個人護理成分的生產(chǎn)，如為香水香料制造商提供從植物來源的香料原料，天然復(fù)配膳食補充劑生產(chǎn)，如固體飲料。欲了解更多信息，請訪問公司網(wǎng)站：www.bnlus.com.
安全港聲明
本新聞稿包含了1995年《私人證券訴訟改革法案》中的前瞻性聲明。前瞻性聲明包括了有關(guān)公司計劃、目標、戰(zhàn)略、未來事件或業(yè)績的聲明，以及其他假設(shè)和不包含歷史事件的聲明。當公司使用諸如"可能"、"將"、"打算"、"應(yīng)該"、"相信"、"期望"、"預(yù)期"、"計劃"、"估計"等或其他類似的表達方式，并不與歷史事件有關(guān)，就是在做前瞻性聲明。前瞻性聲明不是對公司未來業(yè)績的保證，涉及風險和不確定性，可能會導(dǎo)致實際結(jié)果與前瞻性聲明中討論的公司預(yù)期有實質(zhì)性的差異。這些陳述受不確定性和風險因素的印象，包括但不限于：公司的目標和戰(zhàn)略、公司的未來業(yè)務(wù)發(fā)展、公司產(chǎn)品和服務(wù)的需求、技術(shù)的變化、經(jīng)濟狀況、中國天然健康和個人護理行業(yè)的發(fā)展及公司希望發(fā)展的其他國際市場、聲譽和品牌、競爭和定價的影響、政府法規(guī)、中國及公司希望發(fā)展的其他國際市場的經(jīng)濟和商業(yè)狀況的變動，以及與上述任何情況相關(guān)的假設(shè)和公司提交給SEC報告中所陳述的其他風險。因此，我們提醒投資者不要過分依賴本新聞稿中的前瞻性陳述。公司向SEC提交的文件中討論了其他因素，這些文件可在www.sec.gov 上查閱。公司不承擔公開修訂本聲明日期之后出現(xiàn)的事件或情況的前瞻性聲明的義務(wù)。
更多信息，請聯(lián)系：
In the United States: |
|
Maggie Zhang | Impact IR |
Sophie Zhang | Impact IR |
Phone: (646) 893-8916 |
Phone: (786) 953-2513 |
Email: maggie.zhang@irimpact.com |
Email: sophie.zhang@irimpact.com |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES |
||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
||||||||
(UNAUDITED) |
||||||||
March 31, 2022 |
September 30, 2021 |
|||||||
As Of |
||||||||
March 31, 2022 |
September 30, 2021 |
|||||||
ASSETS |
||||||||
CURRENT ASSETS |
||||||||
Cash |
$ |
1,609,079 |
$ |
1,903,867 |
||||
Short-term investments |
132,114 |
1,703,314 |
||||||
Accounts receivable, net |
7,534,786 |
6,152,807 |
||||||
Inventories, net |
2,143,385 |
1,596,492 |
||||||
Advance to suppliers, net |
3,187,116 |
4,094,312 |
||||||
Deferred offering costs |
- |
- |
||||||
Acquisition deposit |
1,000,000 |
1,000,000 |
||||||
Prepaid expenses and other current assets |
95,286 |
98,960 |
||||||
TOTAL CURRENT ASSETS |
15,701,766 |
16,549,752 |
||||||
Property, plant and equipment, net |
23,069,191 |
19,228,642 |
||||||
Intangible assets, net |
416,024 |
411,056 |
||||||
Right-of-use lease assets, net |
171,380 |
201,007 |
||||||
Deferred tax assets, net |
22,774 |
22,342 |
||||||
TOTAL ASSETS |
$ |
39,381,135 |
$ |
36,412,799 |
||||
LIABILITIES AND EQUITY |
||||||||
CURRENT LIABILITIES |
||||||||
Short-term loans |
$ |
1,615,503 |
$ |
41,381 |
||||
Current portion of long-term loans |
1,845,275 |
448,005 |
||||||
Accounts payable |
553,750 |
380,385 |
||||||
Due to related parties |
272,942 |
245,104 |
||||||
Taxes payable |
3,328,986 |
5,052,018 |
||||||
Deferred revenue |
673,974 |
1,096,101 |
||||||
Accrued expenses and other current liabilities |
73,710 |
41,711 |
||||||
Finance lease liabilities, current |
114,216 |
161,286 |
||||||
Operating lease liability, current |
69,167 |
62,871 |
||||||
TOTAL CURRENT LIABILITIES |
$ |
8,547,523 |
$ |
7,528,862 |
||||
Long-term loans |
1,080,402 |
2,173,532 |
||||||
Finance lease liabilities, noncurrent |
- |
28,953 |
||||||
Operating lease liability, noncurrent |
113,478 |
146,703 |
||||||
TOTAL LIABILITIES |
9,741,403 |
9,878,050 |
||||||
COMMITMENTS AND CONTINGENCIES |
||||||||
EQUITY |
||||||||
Ordinary shares, $0.0001 par value, 500,000,000 shares authorized, |
$ |
835 |
$ |
833 |
||||
Additional paid in capital |
15,630,251 |
15,540,433 |
||||||
Statutory reserve |
1,050,721 |
1,050,721 |
||||||
Retained earnings |
11,741,354 |
9,192,676 |
||||||
Accumulated other comprehensive income |
710,020 |
222,221 |
||||||
TOTAL BON NATURAL LIFE LIMITED SHAREHOLDERS' EQUITY |
29,133,181 |
26,006,884 |
||||||
Non-controlling interest |
506,551 |
527,865 |
||||||
Total equity |
29,639,732 |
26,534,749 |
||||||
TOTAL LIABILITIES AND EQUITY |
$ |
39,381,135 |
$ |
36,412,799 |
||||
BON NATURAL LIFE LIMITED AND SUBSIDIARIES |
||||||||
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME |
||||||||
(UNAUDITED) |
||||||||
2022 |
2021 |
|||||||
For the six months ended March 31, |
||||||||
2022 |
2021 |
|||||||
REVENUE |
$ |
13,688,400 |
$ |
11,698,830 |
||||
COST OF REVENUE |
(9,652,453) |
(8,325,148) |
||||||
GROSS PROFIT |
4,035,947 |
3,373,682 |
||||||
OPERATING EXPENSES |
||||||||
Selling expenses |
(83,970) |
(52,666) |
||||||
General and administrative expenses |
(998,943) |
(679,635) |
||||||
Research and development expenses |
(164,675) |
(106,998) |
||||||
Total operating expenses |
(1,247,588) |
(839,299) |
||||||
INCOME FROM OPERATIONS |
2,788,359 |
2,534,383 |
||||||
OTHER INCOME (EXPENSES) |
||||||||
Interest income |
589 |
294 |
||||||
Interest expense |
(277,764) |
(197,168) |
||||||
Unrealized foreign transaction exchange loss |
(16,994) |
(65,691) |
||||||
Government subsidies |
542,256 |
446,910 |
||||||
Income from short-term investments |
12,419 |
- |
||||||
Other income |
43,532 |
41,548 |
||||||
Total other income, net |
304,038 |
225,893 |
||||||
INCOME BEFORE INCOME TAX PROVISION |
3,092,397 |
2,760,276 |
||||||
INCOME TAX PROVISION |
(562,737) |
(465,077) |
||||||
NET INCOME |
2,529,660 |
2,295,199 |
||||||
Less: net loss attributable to non-controlling interest |
(19,018) |
(16,200) |
||||||
NET INCOME ATTRIBUTABLE TO BON NATURAL LIFE |
$ |
2,548,678 |
$ |
2,311,399 |
||||
NET INCOME |
2,529,660 |
2,295,199 |
||||||
OTHER COMPREHENSIVE INCOME |
||||||||
Total foreign currency translation adjustment |
485,503 |
406,143 |
||||||
TOTAL COMPREHENSIVE INCOME |
3,015,163 |
2,701,342 |
||||||
Less: comprehensive loss attributable to non-controlling interest |
(21,314) |
(13,580) |
||||||
COMPREHENSIVE INCOME ATTRIBUTABLE TO BON |
$ |
3,036,477 |
$ |
2,714,922 |
||||
EARNINGS PER SHARE |
||||||||
Basic |
$ |
0.31 |
$ |
0.40 |
||||
Diluted |
$ |
0.30 |
$ |
0.40 |
||||
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING |
||||||||
Basic |
8,350,381 |
5,800,000 |
||||||
Diluted |
8,386,306 |
5,800,000 |
||||||
BON NATURAL LIFE LIMITED AND SUBSIDIARIES |
||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||||||
(UNAUDITED) |
||||||||
2022 |
2021 |
|||||||
For the six months ended March 31, |
||||||||
2022 |
2021 |
|||||||
Cash flows from operating activities |
||||||||
Net income |
$ |
2,529,660 |
$ |
2,295,199 |
||||
Adjustments to reconcile net income to cash provided by operating activities |
||||||||
Allowance for doubtful accounts |
187 |
6,323 |
||||||
Depreciation and amortization |
112,945 |
117,888 |
||||||
Deferred income tax |
(28) |
13,879 |
||||||
Amortization of operating lease right-of-use assets |
33,122 |
26,195 |
||||||
Amortization of stock options |
89,820 |
- |
||||||
Unrealized foreign currency exchange loss |
16,994 |
65,691 |
||||||
Gain on disposal of property and equipment |
(745) |
- |
||||||
Changes in operating assets and liabilities: |
||||||||
Accounts receivable |
(1,265,109) |
(2,898,493) |
||||||
Inventories |
(515,690) |
(391,958) |
||||||
Advance to suppliers, net |
977,033 |
1,738,442 |
||||||
Prepaid expenses and other current assets |
(38,795) |
(99,108) |
||||||
Accounts payable |
165,741 |
(760,103) |
||||||
Operating lease liabilities |
(30,589) |
(21,975) |
||||||
Taxes payable |
(1,806,543) |
1,120,847 |
||||||
Deferred revenue |
(440,032) |
403,246 |
||||||
Accrued expenses and other current liabilities |
41,452 |
383,696 |
||||||
Net cash provided by (used in) operating activities |
(130,577) |
1,999,769 |
||||||
Cash flows from investing activities |
||||||||
Purchase of short-term investments |
(3,678,199) |
- |
||||||
Proceeds upon redemption of short-term investments |
5,273,186 |
- |
||||||
Purchase of property and equipment |
(10,231) |
(715) |
||||||
Proceeds from sales of property and equipment |
1,659 |
|||||||
Capital expenditures on construction-in-progress |
(3,577,995) |
- |
||||||
Net cash used in investing activities |
(1,991,580) |
(715) |
||||||
Cash flows from financing activities |
||||||||
Proceeds from short-term loans |
1,608,378 |
943,517 |
||||||
Proceeds from long-term loans |
594,864 |
685,067 |
||||||
Repayment of short-term loans |
(41,945) |
(457,729) |
||||||
Repayment of long-term loans |
(339,343) |
(109,382) |
||||||
Proceeds from (repayment of) borrowings from related parties |
91,965 |
(1,391,813) |
||||||
Proceeds from (repayment of) third party loans |
- |
(716,574) |
||||||
Principal payment from (repayment of) capital lease |
(89,465) |
254,970 |
||||||
Payment for deferred offering costs |
- |
(155,557) |
||||||
Net cash provided by (used in) financing activities |
1,824,454 |
(947,501) |
||||||
Effect of changes of foreign exchange rates on cash |
2,915 |
(64,052) |
||||||
Net increase (decrease) in cash |
(294,788) |
987,501 |
||||||
Cash, beginning of year |
1,903,867 |
53,106 |
||||||
Cash, end of year |
$ |
1,609,079 |
$ |
1,040,607 |
||||
Supplemental disclosure of cash flow information |
||||||||
Cash paid for interest expense |
$ |
277,764 |
$ |
215,268 |
||||
Cash paid for income tax |
$ |
785,853 |
$ |
1,424 |
||||
Supplemental disclosure of non-cash investing and financing activities |
||||||||
Amortization of share-based compensation for initial public offering services |
$ |
89,820 |
$ |
316,668 |
||||
Right-of-use assets obtained in exchange for operating lease obligations |
$ |
- |
$ |
255,811 |
||||
